Inviragen Inc., a privately held biopharmaceutical company with facilities in Madison, has agreed to be bought by Takeda Pharmaceutical Co. Ltd. for an upfront payment of $35 million, and future payments of up to $215 million tied to meeting future clinical milestones. Read the full Milwaukee Journal Sentinel story here.